Pierre Beaurang hits the ground running at his 3rd startup; Mike Grey poaches Astellas dealmaker to head protein degradation player
As Nitrome Biosciences — a biotech founded in 2017 to focus on a class of enzymes called nitrases — rebrands to Nitrase Therapeutics, the company is also bringing on a new CEO: Pierre Beaurang.
In Nitrase’s statement earlier this week announcing its new CEO, the biotech said that the founder and now-former CEO — Irene Griswold-Prenner — will stay on with Nitrase as the new CSO. And this new appointment comes in tandem with the biotech’s Series A expansion, where Bristol Myers Squibb became an investor alongside AbbVie and Sofinnova Partners, bringing the total amount raised to $45 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.